• Radiation plus PCV improves long-term overall survival in patients with low grade glioma

    • May 02, 2016
    • Nader Sanai, MD

    • Tumor

    As a follow-up to the 2012 results of a randomized Phase III trial adding procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy after radiotherapy for newly-diagnosed patients with WHO grade II glioma, this new report details the long-term results after 12 years of median clinical follow-up.  Patients were randomly assigned to postoperative radiotherapy vs radiotherapy plus PCV.  The results indicate that the combined therapy regimen substantially improves overall survival for low-grade glioma patients under 40 years following biopsy/subtotal resection or any low-grade glioma patient over 40 years of age.   The median overall survival of was 5.5 years longer (13.3 years versus 7.8 years) in patients who received the combination therapy (P=0.003).  While these results suggest the combined regimen should be considered the new standard-of-care for low-grade gliomas, questions such as the long-term neurocognitive effects, the comparability of temozolomide, as well as the underlying genetics of this effect remain to be answered. 

    Source

    New England Journal of Medicine

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site here. Privacy Policy